125 related articles for article (PubMed ID: 23664989)
1. Immunogenicity of sequences around HIV-1 protease cleavage sites: potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites.
Luo M; Capina R; Daniuk C; Tuff J; Peters H; Kimani M; Wachihi C; Kimani J; Ball TB; Plummer FA
Vaccine; 2013 Jun; 31(29):3000-8. PubMed ID: 23664989
[TBL] [Abstract][Full Text] [Related]
2. HLA supertypes contribute in HIV type 1 cytotoxic T lymphocyte epitope clustering in Nef and Gag proteins.
Chakraborty S; Rahman T; Chakravorty R; Kuchta A; Rabby A; Sahiuzzaman M
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):270-8. PubMed ID: 23061377
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites.
Daniel M; Liang B; Luo M
Vaccine; 2021 May; 39(19):2676-2683. PubMed ID: 33863573
[TBL] [Abstract][Full Text] [Related]
4. The effect of HLA polymorphisms on the recognition of Gag epitopes in HIV-1 CRF01_AE infection.
Sriwanthana B; Mori M; Tanaka M; Nishimura S; Miura T; Pathipvanich P; Sawanpanyalert P; Ariyoshi K
PLoS One; 2012; 7(7):e41696. PubMed ID: 22848569
[TBL] [Abstract][Full Text] [Related]
5. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
Hertz T; Logan MG; Rolland M; Magaret CA; Rademeyer C; Fiore-Gartland A; Edlefsen PT; DeCamp A; Ahmed H; Ngandu N; Larsen BB; Frahm N; Marais J; Thebus R; Geraghty D; Hural J; Corey L; Kublin J; Gray G; McElrath MJ; Mullins JI; Gilbert PB; Williamson C
Vaccine; 2016 Nov; 34(47):5792-5801. PubMed ID: 27756485
[TBL] [Abstract][Full Text] [Related]
6. For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.
Luo M; Daniuk CA; Diallo TO; Capina RE; Kimani J; Wachihi C; Kimani M; Bielawny T; Peterson T; Mendoza MG; Kiazyk S; Ball TB; Plummer FA
J Virol; 2012 Jan; 86(2):1166-80. PubMed ID: 22072744
[TBL] [Abstract][Full Text] [Related]
7. Short communication: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa.
Kilpeläinen A; Axelsson Robertson R; Leitner T; Sandström E; Maeurer M; Wahren B
AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1065-71. PubMed ID: 24866397
[TBL] [Abstract][Full Text] [Related]
8. Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico.
Soto-Nava M; Avila-Ríos S; Valenzuela-Ponce H; García-Morales C; Carlson JM; Tapia-Trejo D; Garrido-Rodriguez D; Alva-Hernández SN; García-Tellez TA; Murakami-Ogasawara A; ; Mallal SA; John M; Brockman MA; Brumme CJ; Brumme ZL; Reyes-Teran G;
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093100
[TBL] [Abstract][Full Text] [Related]
9. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach.
De Groot AS; Jesdale B; Martin W; Saint Aubin C; Sbai H; Bosma A; Lieberman J; Skowron G; Mansourati F; Mayer KH
Vaccine; 2003 Oct; 21(27-30):4486-504. PubMed ID: 14505932
[TBL] [Abstract][Full Text] [Related]
10. In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate.
Larijani MS; Sadat SM; Bolhassani A; Pouriayevali MH; Bahramali G; Ramezani A
Curr HIV Res; 2018; 16(5):322-337. PubMed ID: 30605062
[TBL] [Abstract][Full Text] [Related]
11. Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.
Mueller SM; Schaetz B; Eismann K; Bergmann S; Bauerle M; Schmitt-Haendle M; Walter H; Schmidt B; Korn K; Sticht H; Spriewald B; Harrer EG; Harrer T
J Virol; 2007 Mar; 81(6):2887-98. PubMed ID: 17202219
[TBL] [Abstract][Full Text] [Related]
12. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.
Novitsky V; Rybak N; McLane MF; Gilbert P; Chigwedere P; Klein I; Gaolekwe S; Chang SY; Peter T; Thior I; Ndung'u T; Vannberg F; Foley BT; Marlink R; Lee TH; Essex M
J Virol; 2001 Oct; 75(19):9210-28. PubMed ID: 11533184
[TBL] [Abstract][Full Text] [Related]
13. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HIV-1 nef and gag Variations and Host HLA Characteristics as Determinants of Disease Progression among HIV-1 Vertically Infected Kenyan Children.
Saina MC; Bi X; Lihana R; Lwembe R; Ishizaki A; Panikulam A; Palakudy T; Musoke R; Owens M; Songok EM; Ichimura H
PLoS One; 2015; 10(8):e0137140. PubMed ID: 26317223
[TBL] [Abstract][Full Text] [Related]
15. Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.
Borthwick N; Lin Z; Akahoshi T; Llano A; Silva-Arrieta S; Ahmed T; Dorrell L; Brander C; Murakoshi H; Takiguchi M; Hanke T
PLoS One; 2017; 12(4):e0176418. PubMed ID: 28448594
[TBL] [Abstract][Full Text] [Related]
16. QUASI analysis of host immune responses to Gag polyproteins of human immunodeficiency virus type 1 by a systematic bioinformatics approach.
Liang B; Luo M; Ball TB; Jones SJ; Plummer FA
Biochem Cell Biol; 2010 Aug; 88(4):671-81. PubMed ID: 20651839
[TBL] [Abstract][Full Text] [Related]
17. Profile of T cell recognition of HIV type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population.
Serwanga J; Mugaba S; Pimego E; Nanteza B; Lyagoba F; Nakubulwa S; Heath L; Nsubuga RN; Ndembi N; Gotch F; Kaleebu P
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):384-92. PubMed ID: 21867408
[TBL] [Abstract][Full Text] [Related]
18. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.
Huang Y; Duerr A; Frahm N; Zhang L; Moodie Z; De Rosa S; McElrath MJ; Gilbert PB
PLoS One; 2014; 9(11):e108631. PubMed ID: 25369172
[TBL] [Abstract][Full Text] [Related]
19. Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials.
Zembe L; Burgers WA; Jaspan HB; Bekker LG; Bredell H; Stevens G; Gilmour J; Cox JH; Fast P; Hayes P; Vardas E; Williamson C; Gray CM
PLoS One; 2011; 6(10):e26096. PubMed ID: 22022524
[TBL] [Abstract][Full Text] [Related]
20. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.
Thakar MR; Bhonge LS; Lakhashe SK; Shankarkumar U; Sane SS; Kulkarni SS; Mahajan BA; Paranjape RS
J Infect Dis; 2005 Sep; 192(5):749-59. PubMed ID: 16088824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
